MENU

Moderna shares tank after FDA delays COVID vaccine for 12- to 17-year-olds

Shares in Moderna Inc. dropped at least 5% as trading opened Monday after a delay in the decision to approve the COVID-19 vaccine for adolescents ages 12-17.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story